Literature DB >> 25957220

Increased superoxide production and altered nitric oxide-mediated relaxation in the aorta of young but not old male relaxin-deficient mice.

Hooi H Ng1, Maria Jelinic1, Laura J Parry1, Chen-Huei Leo2.   

Abstract

The vascular effects of exogenous relaxin (Rln) treatment are well established and include decreased myogenic reactivity and enhanced relaxation responses to vasodilators in small resistance arteries. These vascular responses are reduced in older animals, suggesting that Rln is less effective in mediating arterial function with aging. The present study investigated the role of endogenous Rln in the aorta and the possibility that vascular dysfunction occurs more rapidly with aging in Rln-deficient (Rln(-/-)) mice. We compared vascular function and underlying vasodilatory pathways in the aorta of male wild-type (Rln(+/+)) and Rln(-/-) mice at 4 and 16 mo of age using wire myography. Superoxide production, but not nitrotyrosine or NADPH oxidase expression, was significantly increased in the aorta of young Rln(-/-) mice, whereas endothelial nitric oxide (NO) synthase and basal NO availability were both significantly decreased compared with Rln(+/+) mice. In the presence of the cyclooxygenase inhibitor indomethacin, sensitivity to ACh was significantly decreased in young Rln(-/-) mice, demonstrating altered NO-mediated relaxation that was normalized in the presence of a membrane-permeable SOD or ROS scavenger. These vascular phenotypes were not exacerbated in old Rln(-/-) mice and, in most cases, did not differ significantly from old Rln(+/+) mice. Despite the vascular phenotypes in Rln(-/-) mice, endothelium-dependent and -independent vasodilation were not adversely affected. Our data show a role for endogenous Rln in reducing superoxide production and maintaining NO availability in the aorta but also demonstrate that Rln deficiency does not compromise vascular function in this artery or exacerbate endothelial dysfunction associated with aging.
Copyright © 2015 the American Physiological Society.

Entities:  

Keywords:  aorta; endothelium; nitric oxide; relaxin; superoxide

Mesh:

Substances:

Year:  2015        PMID: 25957220     DOI: 10.1152/ajpheart.00786.2014

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  16 in total

Review 1.  Vascular actions of relaxin: nitric oxide and beyond.

Authors:  C H Leo; M Jelinic; H H Ng; S A Marshall; J Novak; M Tare; K P Conrad; L J Parry
Journal:  Br J Pharmacol       Date:  2016-09-30       Impact factor: 8.739

2.  Human recombinant relaxin-2 does not attenuate hypertension or renal injury but exacerbates vascular dysfunction in a female mouse model of SLE.

Authors:  Victoria L Wolf; Taylor L Phillips; Erin B Taylor; Jennifer M Sasser; Michael J Ryan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-05-24       Impact factor: 4.733

3.  Relaxin reduces endothelium-derived vasoconstriction in hypertension: Revealing new therapeutic insights.

Authors:  Chen Huei Leo; Hooi Hooi Ng; Sarah A Marshall; Maria Jelinic; Thusitha Rupasinghe; Chengxue Qin; Ute Roessner; Rebecca H Ritchie; Marianne Tare; Laura J Parry
Journal:  Br J Pharmacol       Date:  2019-10-31       Impact factor: 8.739

Review 4.  The actions of relaxin on the human cardiovascular system.

Authors:  Mohsin Sarwar; Xiao-Jun Du; Thomas B Dschietzig; Roger J Summers
Journal:  Br J Pharmacol       Date:  2016-07-11       Impact factor: 8.739

5.  Time-dependent activation of prostacyclin and nitric oxide pathways during continuous i.v. infusion of serelaxin (recombinant human H2 relaxin).

Authors:  C H Leo; M Jelinic; H H Ng; M Tare; L J Parry
Journal:  Br J Pharmacol       Date:  2016-02-17       Impact factor: 8.739

Review 6.  Targeting the relaxin/insulin-like family peptide receptor 1 and 2 with small molecule compounds.

Authors:  Hooi Hooi Ng; Maria Esteban-Lopez; Alexander I Agoulnik
Journal:  Mol Cell Endocrinol       Date:  2018-12-24       Impact factor: 4.102

7.  Serelaxin treatment reverses vascular dysfunction and left ventricular hypertrophy in a mouse model of Type 1 diabetes.

Authors:  Hooi Hooi Ng; Chen Huei Leo; Darnel Prakoso; Chengxue Qin; Rebecca H Ritchie; Laura J Parry
Journal:  Sci Rep       Date:  2017-01-09       Impact factor: 4.379

8.  Serelaxin Treatment Reduces Oxidative Stress and Increases Aldehyde Dehydrogenase-2 to Attenuate Nitrate Tolerance.

Authors:  Chen Huei Leo; Dhanushke T Fernando; Lillie Tran; Hooi Hooi Ng; Sarah A Marshall; Laura J Parry
Journal:  Front Pharmacol       Date:  2017-03-21       Impact factor: 5.810

9.  Relaxin ameliorates high glucose-induced cardiomyocyte hypertrophy and apoptosis via the Notch1 pathway.

Authors:  Xiao Wei; Yuan Yang; Yin-Jiu Jiang; Jian-Ming Lei; Jing-Wen Guo; Hua Xiao
Journal:  Exp Ther Med       Date:  2017-11-06       Impact factor: 2.447

Review 10.  Relaxin as a Therapeutic Target for the Cardiovascular Complications of Diabetes.

Authors:  Hooi Hooi Ng; Chen Huei Leo; Laura J Parry; Rebecca H Ritchie
Journal:  Front Pharmacol       Date:  2018-05-15       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.